

Press Release

07 • 20 • 2006



GENIZON
BioSciences

Genizon BioSciences Inc.
880 McCaffrey St.
St. Laurent, Quebec H4T 2C7
Tel : (514) 270-3991
Fax : (514) 270-5291
1-888-244-0388
www.genizon.com

GENIZON NOW OFFERING HIGH THROUGHPUT SNP GENOTYPING SERVICES

Company provides access to industry leading genotyping and genetic analysis with capacity of 100 million SNP genotypes per day

Montreal, Quebec – July 20, 2006 – Genizon BioSciences today announced it is providing Single Nucleotide Polymorphism (SNP) genotyping services for research organizations and the biopharmaceutical industry. In addition, Genizon offers statistical analysis services using its proven and automated genetic computational pipeline. All services are performed at Genizon's Montreal-based GLP-compliant facilities.

Genotyping is carried out using eight Illumina BeadArray instruments and custom or off the shelf Illumina Infinium™ chips or GoldenGate™ marker sets, for whole genome studies, candidate gene investigation and other applications. The platform operates on a 24/7 basis with a throughput of up to 100 million genotypes per day.

Genetic analysis is performed using GeneSys, the company's validated software platform running in a high-throughput cluster computing environment. Basic analysis includes phase determination, single and multi-marker haplotype analysis, as well as genome-wide or study-wide statistical significance analysis. Customers are also offered the option to run more advanced custom developed algorithms.

"Providing SNP genotyping and genetic analysis services is a natural extension for our company," said Dr. John Hooper, President and CEO of Genizon. "The high quality of our genotyping in combination with our genetic analysis tools has enabled Genizon to become the industry leader in statistical power for gene discovery. We are pleased to extend to others the near 100% call rates, genotyping accuracy and data reproducibility we have achieved in our own studies. We have developed unrivaled expertise in SNP genotyping and genetic analysis, conducting seven whole genome association studies which have resulted in over 50 gene discoveries in common diseases."

Genizon's genotyping service unit is run by Dr. René Paulussen, Vice President, Operations, who has extensive experience in high-throughput laboratory operations in the contract research business.

About Genizon BioSciences

Genizon BioSciences Inc., founded in 1999, is the only source for GeneMaps—comprehensive maps of genes, biochemical pathways and drug targets that are unequivocally involved in causing human disease—accelerating the development of safer, more effective medicines. Genizon's proprietary, automated gene discovery platform using whole-genome association studies involving thousands of members of the Quebec Founder Population provides unprecedented understanding of the genetic origins and mechanisms of

common diseases, resulting in the best possible drug targets. The company's GeneMaps provide pharmaceutical partners with intellectual property that creates opportunities for leadership in many therapeutic areas by bringing to market better treatments that address the root causes of diseases. Genizon is conducting gene discovery programs in more than 20 common diseases. Genizon's genotyping and genetic analysis services also assist partners in rapidly generating statistically reliable gene discoveries from the partner's DNA collections.

Contacts:

Genizon BioSciences, Inc.

Diane Bouchard
Director, Biotechnology Services
+1 514 270 3991 ext. 287
diane.bouchard@genizon.com

Schwartz Communications

Lauren Arnold/Wendy Mejia
+1 781 684 0770
genizon@schwartz-pr.com